Multimodal MRI-based imputation of the Aβ+ in early mild cognitive impairment

Annals of Clinical and Translational Neurology

Volumn 1, Issue 3, 2014, Pages 160-170

  Tosun, Duygu ^a   Joshi, Sarang ^b   Weiner, Michael W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; FLORBETAPIR F 18;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOIDOSIS; ARTERIAL SPIN LABELING; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; CEREBROSPINAL FLUID; FEMALE; FRONTOPARIETAL CORTEX; HUMAN; IMAGE ANALYSIS; IN-LAW; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTIMODAL IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL LEAST SQUARES REGRESSION; PERFUSION; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; VOXEL BASED MORPHOMETRY;

EID: 85008693755     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.40     Document Type: Article

References (59)

1. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 2011;70:960–969.
2. Pike KE, Savage G, Villemagne VL, et al. β-Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007;130:2837–2844.
3. Morris J, Price J. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 2001;17:101–118.
4. Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009;66:1469–1475.
5. Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol 2012;11:669–678.
6. Driscoll I, Troncoso J, Rudow G, et al. Correspondence between in vivo 11C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. Acta Neuropathol 2012;124:823–831.
7. Clark CM, Xie S, Chittams J, et al. Cerebrospinal fluid tau and β-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 2003;60:1696–1702.
8. Peskind ER, Riekse R, Quinn JF, et al. Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord 2005;19:220–225.
9. Griffey RT, Sodickson A. Cumulative radiation exposure and cancer risk estimates in emergency department patients undergoing repeat or multiple CT. AJR Am J Roentgenol 2009;192:887–892.
10. Becker JA, Hedden T, Carmasin J, et al. Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol 2011;69:1032–1042.
11. Oh H, Mormino EC, Madison C, et al. β-Amyloid affects frontal and posterior brain networks in normal aging. Neuroimage 2011;54:1887–1895.
12. Whitwell JL, Tosakulwong N, Weigand SD, et al. Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects? Neuroimage Clin 2013;2:249–257.
13. Sabuncu MR, Desikan RS, Sepulcre J, et al. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol 2011;68:1040–1048.
14. Chetelat G, Villemagne VL, Villain N, et al. Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition. Neurology 2012;78:477–484.
15. Andrews KA, Modat M, Macdonald KE, et al. Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials. PLoS One 2013;8:e58816.
16. 1-42. Ann Neurol 2010;68:825–834.
17. Sojkova J, Beason-Held L, Zhou Y, et al. Longitudinal cerebral blood flow and amyloid deposition: an emerging pattern? J Nucl Med 2008;49:1465–1471.
18. McLaren D, Schultz AChhatwal J, et al., eds. ApoE e4 and amyloid burden independently increase cerebral blood flow in cognitively normal older adults. Seventh Human Amyloid Imaging; Miami, 2013.
19. Sojkova J, Goh J, Beason-Held L, et al., eds. Increased beta-amyloid deposition is related to regional cerebral blood flow in nondemented older adults. Human Amyloid Imaging 2011 Meeting; Miami, 2011.
20. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–308.
21. Bourgeat P, Chetelat G, Villemagne VL, et al. β-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010;74:121–127.
22. Honea RA, Vidoni E, Harsha A, Burns JM. Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study. J Alzheimers Dis 2009;18:553–564.
23. Bangen KJ, Restom K, Liu TT, et al. Assessment of Alzheimer's disease risk with functional magnetic resonance imaging: an arterial spin labeling study. J Alzheimers Dis 2012;31(Suppl. 3):S59–S74.
24. Jagust WJ, Bandy D, Chen K, et al. The Alzheimer's disease neuroimaging initiative positron emission tomography core. Alzheimers Dement 2010;6:221–229.
25. Landau SM, Breault C, Joshi AD, et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med 2013;54:70–77.
26. Jack CR, Bernstein MA, Fox NC, et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging 2008;27:685–691.
27. Shattuck DW, Leahy RM. BrainSuite: an automated cortical surface identification tool. Med Image Anal 2002;6:129–142.
28. Jiang T, Navab N, Pluim J, et al., eds. Multivariate statistical analysis of deformation momenta relating anatomical shape to neuropsychological measures. Medical image computing and computer-assisted intervention – MICCAI 2010. Berlin/Heidelberg: Springer, 2010. p. 529–537.
29. Tosun D, Mojabi P, Weiner MW, Schuff N. Joint analysis of structural and perfusion MRI for cognitive assessment and classification of Alzheimer's disease and normal aging. Neuroimage 2010;52:186–197.
30. Johnson NA, Jahng GH, Weiner MW, et al. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 2005;234:851–859.
31. Hayasaka S, Du A-T, Duarte A, et al. A non-parametric approach for co-analysis of multi-modal brain imaging data: application to Alzheimer's disease. Neuroimage 2006;30:768–779.
32. Du AT, Jahng GH, Hayasaka S, et al. Hypoperfusion in frontotemporal dementia and Alzheimer disease by arterial spin labeling MRI. Neurology 2006;67:1215–1220.
33. Tosun D, Rosen H, Miller BL, et al. MRI patterns of atrophy and hypoperfusion associations across brain regions in frontotemporal dementia. Neuroimage 2012;59:2098–2109.
34. Tao R, Fletcher P, Gerber S, Whitaker R, eds. A variational image-based approach to the correction of susceptibility artifacts in the alignment of diffusion weighted and structural MRI. Inf Process Med Imaging 2009;21:664–675.
35. Li K-L, Zhu X, Hylton N, et al. Four-phase single-capillary stepwise model for kinetics in arterial spin labeling MRI. Magn Reson Med 2005;53:511–518.
36. Pham DL, Prince JL. Adaptive fuzzy segmentation of magnetic resonance images. IEEE Trans Med Imaging 1999;18:737–752.
37. Wold S, Geladi P, Esbensen K, Öhman J. Multi-way principal components-and PLS-analysis. J Chemom 1987;1:41–56.
38. Tosun D, Joshi S, Weiner MW. Neuroimaging predictors of brain amyloidosis in mild cognitive impairment. Ann Neurol 2013;74:188–198.
39. Chetelat G, Villemagne VL, Bourgeat P, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 2010;67:317–324.
40. Tosun D, Schuff N, Mathis CA, et al. Spatial patterns of brain amyloid-β burden and atrophy rate associations in mild cognitive impairment. Brain 2011;134:1077–1088.
41. Tosun D, Schuff N, Truran-Sacrey D, et al. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiol Aging 2010;31:1340–1354.
42. Rowe CC, Ng S, Ackermann U, et al. Imaging β-amyloid burden in aging and dementia. Neurology 2007;68:1718–1725.
43. Johnson KA, Mueller ST, Walshe TM, et al. Cerebral perfusion imaging in Alzheimer's disease. Use of single photon emission computed tomography and iofetamine hydrochloride I 123. Arch Neurol 1987;44:165–168.
44. Dougall N, Nobili F, Ebmeier KP. Predicting the accuracy of a diagnosis of Alzheimer's disease with 99mTc HMPAO single photon emission computed tomography. Psychiatry Res 2004;131:157–168.
45. Ishii K, Sasaki M, Yamaji S, et al. Demonstration of decreased posterior cingulate perfusion in mild Alzheimer's disease by means of H215O positron emission tomography. Eur J Nucl Med 1997;24:670–673.
46. Matsuda H, Mizumura S, Nagao T, et al. Automated discrimination between very early Alzheimer disease and controls using an easy Z-score imaging system for multicenter brain perfusion single-photon emission tomography. AJNR Am J Neuroradiol 2007;28:731–736.
47. Alsop DC, Detre JA, Grossman M. Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging. Ann Neurol 2000;47:93–100.
48. Binnewijzend MA, Kuijer JP, Benedictus MR, et al. Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in Alzheimer disease and mild cognitive impairment: a marker for disease severity. Radiology 2013;267:221–230.
49. Dai W, Lopez OL, Carmichael OT, et al. Mild cognitive impairment and Alzheimer disease: patterns of altered cerebral blood flow at MR imaging. Radiology 2009;250:856–866.
50. Alsop DC, Casement M, de Bazelaire C, et al. Hippocampal hyperperfusion in Alzheimer's disease. Neuroimage 2008;42:1267–1274.
51. Alexopoulos P, Sorg C, Forschler A, et al. Perfusion abnormalities in mild cognitive impairment and mild dementia in Alzheimer's disease measured by pulsed arterial spin labeling MRI. Eur Arch Psychiatry Clin Neurosci 2012;262:69–77.
52. Fleisher AS, Podraza KM, Bangen KJ, et al. Cerebral perfusion and oxygenation differences in Alzheimer's disease risk. Neurobiol Aging 2009;30:1737–1748.
53. Oh H, Habeck C, Madison C, Jagust W. Covarying alterations in Abeta deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. Hum Brain Mapp 2014;35:297–308.
54. Mielke M, Wiste H, Wiegand S, eds. Identification of non-invasive screening variables for the prediction of amyloid accumulation in a population-based study of cognitively normal elderly individuals. Alzheimer's Association International Conference. Vancouver, British Columbia, Canada, 14–19 July 2012.
55. Apostolova L, Hwang K, Kohannim O, eds. Predicting brain amyloidosis in MCI using clinical, cognitive, imaging and peripheral blood protein measures. Alzheimer's Association International Conference. Vancouver, British Columbia, Canada, 14–19 July 2012.
56. Perrotin A, Mormino EC, Madison CM, et al. Subjective cognition and amyloid deposition imaging: a Pittsburgh compound B positron emission tomography study in normal elderly individuals. Arch Neurol 2012;69:223–229.
57. Hedden T, Oh H, Younger AP, Patel TA. Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology 2013;80:1341–1348.
58. Amariglio RE, Becker JA, Carmasin J, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia 2012;50:2880–2886.
59. Mosconi L, Rinne JO, Tsui WH, et al. Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci USA 2010;107:5949–5954.